Vaccination and Multiple Sclerosis - Current Situation

A N Boyko; S A Sivertseva; D S Chemakina; N N Spirin; O V Bykova; M E Guseva

doi:10.1007/s11055-022-01265-9

Vaccination and Multiple Sclerosis - Current Situation

Neurosci Behav Physiol. 2022;52(4):486-490. doi: 10.1007/s11055-022-01265-9. Epub 2022 Jul 20.

Authors

A N Boyko^{1

2}, S A Sivertseva³, D S Chemakina⁴, N N Spirin⁵, O V Bykova⁶, M E Guseva¹

Affiliations

¹ Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
² Federal Center for the Brain and Neurotechnologies, Russian Federal Medical Biological Agency, Moscow, Russia.
³ Tyumen Regional Multiple Sclerosis Center, Neftyanik Clinic, Tyumen, Russia.
⁴ Central Clinical Hospital, Russian Academy of Sciences, Moscow, Russia.
⁵ Yaroslavl State Medical University, Russian Ministry of Health, Yaroslavl, Russia.
⁶ Scientific-Applied Center for Pediatric Psychoneurology, Moscow Health Department, Moscow, Russia.

Abstract

Active immunization of patients with autoimmune diseases is a current challenge. Vaccination of patients with multiple sclerosis (MS) has been shown not to be associated with increased risk of exacerbation. A personalized approach to immunization of this group of patients is required, taking account of ongoing therapy and the nature of the course of illness. MS is not an absolute contraindication for vaccination against the new coronavirus infection. Vaccination can be with any of the currently authorized immunoformulations.

Keywords: COVID-19; autoimmune diseases; multiple sclerosis; vaccination.